vs
ANGIODYNAMICS INC（ANGO）与ARTIVION, INC.（AORT）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是ANGIODYNAMICS INC的1.5倍（$116.0M vs $79.4M）。ARTIVION, INC.净利率更高（2.1% vs -8.0%，领先10.1%）。ARTIVION, INC.同比增速更快（19.2% vs 9.0%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $-7.9M）。过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
ANGO vs AORT — 直观对比
营收规模更大
AORT
是对方的1.5倍
$79.4M
营收增速更快
AORT
高出10.2%
9.0%
净利率更高
AORT
高出10.1%
-8.0%
自由现金流更多
ANGO
多$12.2M
$-7.9M
两年增速更快
AORT
近两年复合增速
2.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $116.0M |
| 净利润 | $-6.3M | $2.4M |
| 毛利率 | 56.4% | 63.1% |
| 营业利润率 | -7.7% | 9.2% |
| 净利率 | -8.0% | 2.1% |
| 营收同比 | 9.0% | 19.2% |
| 净利润同比 | 40.9% | 114.7% |
| 每股收益（稀释后） | $-0.15 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOAORT
| Q4 25 | $79.4M | $116.0M | ||
| Q3 25 | $75.7M | $113.4M | ||
| Q2 25 | $80.2M | $113.0M | ||
| Q1 25 | $72.0M | $99.0M | ||
| Q4 24 | $72.8M | $97.3M | ||
| Q3 24 | $67.5M | $95.8M | ||
| Q2 24 | $71.0M | $98.0M | ||
| Q1 24 | $75.2M | $97.4M |
净利润ANGOAORT
| Q4 25 | $-6.3M | $2.4M | ||
| Q3 25 | $-10.9M | $6.5M | ||
| Q2 25 | $-6.0M | $1.3M | ||
| Q1 25 | $-4.4M | $-505.0K | ||
| Q4 24 | $-10.7M | $-16.5M | ||
| Q3 24 | $-12.8M | $-2.3M | ||
| Q2 24 | $-13.4M | $-2.1M | ||
| Q1 24 | $-187.7M | $7.5M |
毛利率ANGOAORT
| Q4 25 | 56.4% | 63.1% | ||
| Q3 25 | 55.3% | 65.6% | ||
| Q2 25 | 52.7% | 64.7% | ||
| Q1 25 | 54.0% | 64.2% | ||
| Q4 24 | 54.8% | 63.2% | ||
| Q3 24 | 54.4% | 63.7% | ||
| Q2 24 | 54.3% | 64.6% | ||
| Q1 24 | 47.7% | 64.6% |
营业利润率ANGOAORT
| Q4 25 | -7.7% | 9.2% | ||
| Q3 25 | -14.1% | 11.1% | ||
| Q2 25 | -7.2% | 7.4% | ||
| Q1 25 | -13.9% | 2.2% | ||
| Q4 24 | -15.2% | 2.7% | ||
| Q3 24 | -19.4% | 4.6% | ||
| Q2 24 | -20.4% | 6.6% | ||
| Q1 24 | -265.9% | 26.0% |
净利率ANGOAORT
| Q4 25 | -8.0% | 2.1% | ||
| Q3 25 | -14.4% | 5.7% | ||
| Q2 25 | -7.5% | 1.2% | ||
| Q1 25 | -6.1% | -0.5% | ||
| Q4 24 | -14.7% | -16.9% | ||
| Q3 24 | -19.0% | -2.4% | ||
| Q2 24 | -18.9% | -2.2% | ||
| Q1 24 | -249.7% | 7.7% |
每股收益（稀释后）ANGOAORT
| Q4 25 | $-0.15 | $0.06 | ||
| Q3 25 | $-0.26 | $0.13 | ||
| Q2 25 | $-0.15 | $0.03 | ||
| Q1 25 | $-0.11 | $-0.01 | ||
| Q4 24 | $-0.26 | $-0.40 | ||
| Q3 24 | $-0.31 | $-0.05 | ||
| Q2 24 | $-0.35 | $-0.05 | ||
| Q1 24 | $-4.67 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $64.9M |
| 总债务越低越好 | — | $215.1M |
| 股东权益账面价值 | $176.3M | $448.2M |
| 总资产 | $269.7M | $884.8M |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资ANGOAORT
| Q4 25 | $41.6M | $64.9M | ||
| Q3 25 | $38.8M | $73.4M | ||
| Q2 25 | $55.9M | $53.5M | ||
| Q1 25 | $44.8M | $37.7M | ||
| Q4 24 | $54.1M | $53.5M | ||
| Q3 24 | $55.0M | $56.2M | ||
| Q2 24 | $76.1M | $55.0M | ||
| Q1 24 | $78.5M | $51.1M |
总债务ANGOAORT
| Q4 25 | — | $215.1M | ||
| Q3 25 | — | $214.9M | ||
| Q2 25 | — | $215.6M | ||
| Q1 25 | — | $314.7M | ||
| Q4 24 | — | $314.3M | ||
| Q3 24 | — | $314.0M | ||
| Q2 24 | $0 | $313.6M | ||
| Q1 24 | — | $313.3M |
股东权益ANGOAORT
| Q4 25 | $176.3M | $448.2M | ||
| Q3 25 | $178.9M | $438.7M | ||
| Q2 25 | $183.0M | $419.9M | ||
| Q1 25 | $185.9M | $294.3M | ||
| Q4 24 | $186.8M | $276.2M | ||
| Q3 24 | $196.6M | $304.7M | ||
| Q2 24 | $205.6M | $295.1M | ||
| Q1 24 | $218.7M | $295.0M |
总资产ANGOAORT
| Q4 25 | $269.7M | $884.8M | ||
| Q3 25 | $265.6M | $857.7M | ||
| Q2 25 | $280.1M | $838.4M | ||
| Q1 25 | $285.4M | $791.2M | ||
| Q4 24 | $291.6M | $789.1M | ||
| Q3 24 | $293.6M | $803.1M | ||
| Q2 24 | $317.7M | $789.5M | ||
| Q1 24 | $324.8M | $784.0M |
负债/权益比ANGOAORT
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | 0.00× | 1.06× | ||
| Q1 24 | — | 1.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $19.6M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $-7.9M |
| 自由现金流率自由现金流/营收 | 5.3% | -6.9% |
| 资本支出强度资本支出/营收 | 0.5% | 23.7% |
| 现金转化率经营现金流/净利润 | — | 8.06× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $839.0K |
8季度趋势，按日历期对齐
经营现金流ANGOAORT
| Q4 25 | $4.7M | $19.6M | ||
| Q3 25 | $-15.9M | $22.3M | ||
| Q2 25 | $18.8M | $15.0M | ||
| Q1 25 | $-13.2M | $-17.0M | ||
| Q4 24 | $2.5M | $10.1M | ||
| Q3 24 | $-18.3M | $11.5M | ||
| Q2 24 | $5.0M | $6.1M | ||
| Q1 24 | $-12.5M | $-5.5M |
自由现金流ANGOAORT
| Q4 25 | $4.2M | $-7.9M | ||
| Q3 25 | $-16.6M | $17.7M | ||
| Q2 25 | $18.0M | $11.7M | ||
| Q1 25 | $-15.0M | $-20.6M | ||
| Q4 24 | $1.7M | $8.7M | ||
| Q3 24 | $-19.3M | $7.8M | ||
| Q2 24 | $4.4M | $3.6M | ||
| Q1 24 | $-13.1M | $-9.1M |
自由现金流率ANGOAORT
| Q4 25 | 5.3% | -6.9% | ||
| Q3 25 | -22.0% | 15.6% | ||
| Q2 25 | 22.5% | 10.4% | ||
| Q1 25 | -20.8% | -20.8% | ||
| Q4 24 | 2.3% | 9.0% | ||
| Q3 24 | -28.7% | 8.2% | ||
| Q2 24 | 6.2% | 3.7% | ||
| Q1 24 | -17.5% | -9.3% |
资本支出强度ANGOAORT
| Q4 25 | 0.5% | 23.7% | ||
| Q3 25 | 1.0% | 4.1% | ||
| Q2 25 | 1.0% | 2.9% | ||
| Q1 25 | 2.5% | 3.7% | ||
| Q4 24 | 1.1% | 1.5% | ||
| Q3 24 | 1.6% | 3.8% | ||
| Q2 24 | 0.8% | 2.6% | ||
| Q1 24 | 0.8% | 3.7% |
现金转化率ANGOAORT
| Q4 25 | — | 8.06× | ||
| Q3 25 | — | 3.42× | ||
| Q2 25 | — | 11.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
